Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 13, 2017

Study Completion Date

June 5, 2018

Conditions
Hepatitis B
Interventions
BIOLOGICAL

FP-02.2 Vaccine

Synthetic Peptide Hepatitis B Vaccine

OTHER

Placebo

Placebo

OTHER

IC31® Adjuvant

IC31® Adjuvant

Trial Locations (21)

41931

Keimyung University Dongsan Medical Center, Daegu

41944

Kyungpook National University Hospital, Daegu

49241

Pusan National University Busan Hospital, Busan

50612

Pusan National University Yangsan Hospital, Yangsan

152703

Korea University Guro Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Yonsei University Health System Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St. Mary's Hospital, Seoul

07061

SMG-SNU Boramae Medical Center, Seoul

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham

BS1 3NU

University Hospitals Bristol, Bristol

E1 2AT

Barts and The London School of Medicine and Dentistry, Blizzard Institiue, London

King's College Hospital, London

NW3 2QG

Royal Free Hospital, London

SW17 0QT

St. George's Hospital and Medical School, London

W2 1NY

Imperial College London - St Mary's Campus, London

M8 5RB

Pennine Acute Hospitals, Manchester

BD9 6RJ

Bradford Teaching Hospitals, Bradford Royal Infirmary, North Yorks

NG7 2UH

Queen's Medical Centre, Nottingham Hospital, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT02496897 - Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B | Biotech Hunter | Biotech Hunter